1. GPR55 mediates lymphocyte migration inhibition via Gα13.
GPR55 mediates lymphocyte migration inhibition via Gα13. (A and B) Migration of GPR55 and control transduced WEHI231 cells to CXCL12 and the indicated amounts of LPI (mixture of 16:0, 18:0, and 18:2) (A) or 1 μM of the indicated types of LPI (B) in Transwell assays. (C) Migration of empty vector– or GPR55-transduced B cells that either express (Mb1Cre− Gna13f/f) or lack (Mb1Cre+ Gna13f/f) Gα13 to CXCL12 and the indicated amounts of 20:4 LPI. (D) Migration of γδT IELs to vehicle or CXCL10 and the indicated amounts of LPI (16:0, 18:0, and 18:2) or the GPR55 antagonist CID (E) Migration of control (Het) or GPR55 KO γδT IELs to vehicle or CCL25 in the absence or presence of 20:4 LPI. (F) Flow cytometric analysis of pERM levels in WEHI231 cells (top) or CD8αα γδT IELs from control (Het) or GPR55 KO mice (bottom) after treatment for 5 min with vehicle (DMSO) or 20:4 LPI (1 μM). Each experiment was performed in duplicate and repeated at least twice. Numbers inside plots indicate mean ± SEM. GPR55 Het, n = 3; GPR55 KO, n = 3.
Hayakazu Sumida et al. Sci. Immunol. 2017;2:eaao1135
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works